Form 4: Guardant Health Director Ian T. Clark Reports Stock Sale and New Equity Grants

Guardant Health, Inc. Director Ian T. Clark disclosed the sale of common stock and the acquisition of new stock options and restricted stock units, as part of pre-arranged trading plans.

Summary

• Ian T. Clark, a Director of Guardant Health, Inc. (GH), filed a Form 4 disclosing recent transactions.
• On June 17, 2025, Mr. Clark sold 6,672 shares of common stock at a weighted average price of $48.3841 per share, with prices ranging from $48.38 to $48.41.
• Following this sale, Mr. Clark beneficially owns 9,851 shares indirectly through The Thornton-Clark Family Trust.
• On June 18, 2025, Mr. Clark acquired 6,833 stock options with an exercise price of $50.57.
• These stock options vest in full on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier, and expire on June 18, 2035.
• Also on June 18, 2025, Mr. Clark acquired 5,092 Restricted Stock Units (RSUs).
• The RSUs vest in full on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier.
• All transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there was a sale of common stock, it was pre-scheduled under a 10b5-1 plan, mitigating negative implications. Simultaneously, the director received new grants of stock options and restricted stock units, indicating continued alignment with shareholder interests and future equity participation.

Positives

• The acquisition of 6,833 stock options and 5,092 Restricted Stock Units (RSUs) indicates continued equity participation and alignment of interests between the director and shareholders.
• The vesting schedule for the new options and RSUs is relatively short (one year anniversary of grant date or next annual meeting), providing a quicker path to ownership.

Negatives

• The sale of 6,672 shares of common stock by a director could be perceived negatively by investors, although it was conducted under a pre-arranged 10b5-1 plan.

Risks

• While the sale was part of a 10b5-1 plan, significant insider selling, even pre-scheduled, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to short-term stock price volatility.

Future Outlook

The newly acquired stock options and restricted stock units are set to vest in full on June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs earlier, indicating a near-term realization of these equity grants.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions and does not provide broader industry context or trends. It reflects individual equity management by a director within the healthcare technology sector.

Related Party Transactions

• The 9,851 shares of common stock beneficially owned following the reported transaction are held indirectly by The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, can sometimes lead to questions about management's confidence, but the simultaneous grant of new equity awards may offset this concern by demonstrating continued commitment.
• Employees: No direct impact mentioned.

Next Steps

• The acquired stock options and Restricted Stock Units (RSUs) are expected to vest on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Stock Sale, Stock Options, Restricted Stock Units, Director, Ian T. Clark, 10b5-1 Plan